文献速递胸部肿瘤

帕博利珠单抗治疗恶性胸膜间皮瘤患者(KEYNOTE-028)的临床安全性与活性:一项非随机、开放标签、1b期试验的初步结果

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
PubMed 文献 · Lancet Oncol · 2017-03-11

这项非随机、开放标签1b期试验从6国13中心纳入既往治疗过、PD-L1阳性(≥1%肿瘤细胞表达)的恶性胸膜间皮瘤患者,接受帕博利珠单抗10 mg/kg每2周一次治疗,最长2年。截至2016年6月20日,25例可评估患者中16例(64%)发生治疗相关不良事件,5例(20%)为3级;5例(20%)达部分缓解,客观缓解率20%(95%CI 6.8-40.7),13例(52%)疾病稳定,中位缓解持续时间12.0个月(95%CI 3.7至未达到)。作者认为帕博利珠单抗耐受性良好并可能具有抗肿瘤活性,缓解持久性和疗效值得进一步研究。

要点

  • PD-L1阳性(≥1%肿瘤细胞)恶性胸膜间皮瘤患者接受帕博利珠单抗10 mg/kg每2周一次,客观缓解率20%(5/25,95%CI 6.8-40.7)。
  • 16例(64%)发生治疗相关不良事件,5例(20%)为3级;无治疗相关死亡或停药。
  • 中位缓解持续时间12.0个月(95%CI 3.7至未达到),2例患者在数据截止时仍在治疗。

核心结论

  • 帕博利珠单抗在PD-L1阳性恶性胸膜间皮瘤患者中似乎耐受性良好,并可能具有抗肿瘤活性。
  • 作者认为该人群的缓解持久性和疗效值得进一步研究。

研究设计与样本

  • 非随机、开放标签、1b期试验(KEYNOTE-028),纳入既往治疗过的PD-L1阳性恶性胸膜间皮瘤患者。
  • 患者来自6个国家13个中心,接受帕博利珠单抗10 mg/kg每2周一次,最长2年或直至确认进展或不可接受毒性。
  • 关键入选标准包括可测量病灶、标准治疗失败、ECOG体能状态0或1;PD-L1阳性定义为免疫组化肿瘤细胞表达≥1%。
  • 主要终点为安全性和耐受性(全治疗人群分析)及客观缓解(全分析集),疗效按RECIST 1.1由研究者评估。
  • 截至2016年6月20日,25例患者接受帕博利珠单抗治疗。

主要发现

  • 16例(64%)报告治疗相关不良事件,最常见为疲乏6例(24%)、恶心6例(24%)、关节痛5例(20%)。
  • 5例(20%)报告3级治疗相关不良事件;3例(12%)因免疫相关不良事件需中断给药。
  • 5例(20%)达部分缓解,客观缓解率20%(95%CI 6.8-40.7);13例(52%)疾病稳定。
  • 中位缓解持续时间12.0个月(95%CI 3.7至未达到),2例患者在数据截止时仍在治疗。
  • 无治疗相关死亡或治疗相关停药。

关键数值与推荐

  • PD-L1阳性定义为免疫组化肿瘤细胞表达≥1%。
  • 帕博利珠单抗剂量为10 mg/kg每2周一次,最长2年。
  • 客观缓解率20%(95%CI 6.8-40.7),部分缓解5例(20%)。
  • 疾病稳定13例(52%),中位缓解持续时间12.0个月(95%CI 3.7至未达到)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为初步结果(interim analysis)。
  • 作者指出该人群的缓解持久性和疗效值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here on the interim analysis of the malignant pleural mesothelioma cohort. METHODS: Previously treated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 centres in six countries. Patients received pembrolizumab (10 mg/kg every 2 weeks) for up to 2 years or until confirmed progression or unacceptable toxicity. Key eligibility criteria included measurable disease, failure of standard therapy, and Eastern Cooperative Oncology Group performance status of 0 or 1. PD-L1 positivity was defined as expression in 1% or more of tumour cells by immunohistochemistry. Response was assessed based on investigator review using the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Primary endpoints were safety and tolerability, analysed in the all-patients-as-treated population, and objective response, analysed for the full-analysis set. This trial is registered with ClinicalTrials.gov, number NCT02054806, and is ongoing but not recruiting participants. FINDINGS: As of June 20, 2016, 25 patients received pembrolizumab. 16 (64%) patients reported a treatment-related adverse event; the most common adverse event were fatigue (six [24%]), nausea (six [24%]), and arthralgia (five [20%]). Five (20%) patients reported grade 3 treatment-related adverse events. Three (12%) patients required dose interruption because of immune-related adverse events: one (4%) of 25 each had grade 3 rhabdomyolysis and grade 2 hypothyroidism; grade 3 iridocyclitis, grade 1 erythema multiforme, and grade 3 erythema; and grade 2 infusion-related reaction. No treatment-related deaths or discontinuations occurred. Five (20%) patients had a partial response, for an objective response of 20% (95% CI 6·8-40·7), and 13 (52%) of 25 had stable disease. Responses were durable (median response duration 12·0 months [95% CI 3·7 to not reached]); two patients remained on treatment at data cutoff. INTERPRETATION: Pembrolizumab appears to be well tolerated and might confer anti-tumour activity in patients with PD-L1-positive malignant pleural mesothelioma. Response durability and efficacy in this patient population warrants further investigation. FUNDING: Merck.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017. PMID: 28291584. doi:10.1016/S1470-2045(17)30169-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。